Trial of Covid-19 blood plasma finds no benefit in severely ill patients
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
WEDNESDAY, MAY 18, 2022
WEDNESDAY, MAY 18, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Trial of Covid-19 blood plasma finds no benefit in severely ill patients

Coronavirus chronicle

Reuters
11 January, 2021, 08:10 pm
Last modified: 11 January, 2021, 08:18 pm

Related News

  • S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • RMCH shuts down its corona unit
  • Beijing works from home, Shanghai says victory against Covid getting closer
  • N Korea says six dead after admitting Covid outbreak for first time

Trial of Covid-19 blood plasma finds no benefit in severely ill patients

The underlying hypothesis for using convalescent plasma as a potential treatment for Covid-19 patients is that the antibodies it contains could neutralize the virus, stopping it from replicating and halting tissue damage

Reuters
11 January, 2021, 08:10 pm
Last modified: 11 January, 2021, 08:18 pm
Representational image. Photo: Collected
Representational image. Photo: Collected

An international trial testing convalescent blood plasma on Covid-19 patients with moderate and severe illness has halted enrolment of severely ill Covid-19 patients requiring intensive care after it found no benefit, trial investigators said on Monday.

The decision by the REMAP-CAP trial leaders came after an initial analysis of more than 900 severely ill trial participants in intensive care showed that treatment with the product - an antibody-rich plasma taken from people who have recovered from the pandemic disease - did not improve outcomes.

"There was no evidence of harm associated with the administration of convalescent plasma" (and) the trial is continuing to recruit hospitalised Covid-19 patients who are moderately ill but not in intensive care, scientists leading the trial said in a statement.

"It is biologically plausible that patients who are not producing antibodies at the time of convalescent plasma therapy and those patients with excess virus may benefit more than others. Our additional analyses will explore this," said Manu Shankar-Hari, a clinician and professor of critical care medicine at Britain's Guy's and St Thomas' hospital, who is co-leading the trial.

He added that the initial analysis did not assess plasma's effects in hospitalised patients with less severe disease. This "remains a very important question" and would continue to be explored in the ongoing trial, he said.

The underlying hypothesis for using convalescent plasma as a potential treatment for Covid-19 patients is that the antibodies it contains could neutralize the virus, stopping it from replicating and halting tissue damage.

But this initial analysis leading to the REMAP-CAP pause in enrolment of critically ill patients showed there was a very low probability - 2.2% - that it reduced death rates or decreased the number of days patients needed intensive care.

"Why convalescent plasma does not seem to improve outcome in severely ill Covid-19 patients admitted to the ICU is not yet known. However, it may be because the lung damage is too advanced for convalescent plasma to make a difference," said Alexis Turgeon, a critical care doctor and professor at Université Laval in Canada, who is also working on the trial.

REMAP-CAP is an international clinical trial exploring potential treatments for Covid-19. It has already recruited 4,100 Covid-19 patients at more than 290 clinical sites across Europe, the Americas, Asia, Africa and Australasia.

Separate findings from REMAP-CAP showed last week that treating critically ill Covid-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improved survival rates and reduced the amount of time patients need intensive care.

The trial is also looking at potential effects of a range of other existing therapies, including anticoagulation medicines, antiplatelet agents, antibiotics, statins and vitamin C.

Top News

COVID-19 / Covid-19 Plasma Therapy

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Social safety budget to stay same despite inflation rise
    Social safety budget to stay same despite inflation rise
  • RMG makers worried over move on power tariff hike
    RMG makers worried over move on power tariff hike
  • A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
    Dollar hits Tk100 mark in open market

MOST VIEWED

  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    N Korea mobilises army, steps up tracing amid Covid wave
  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June

Related News

  • S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • RMCH shuts down its corona unit
  • Beijing works from home, Shanghai says victory against Covid getting closer
  • N Korea says six dead after admitting Covid outbreak for first time

Features

Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

19h | Panorama
Illustration: TBS

How Putin revived Nato

21h | Panorama
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam

The United House: Living and working inside nature

21h | Habitat
Pcycle team members at a waste management orientation event. Photo: Courtesy

Pcycle: Turning waste from bins into beautiful crafts

22h | Panorama

More Videos from TBS

After six decades ,the Archies is back

After six decades ,the Archies is back

12h | Videos
Exporters in discomfort, expatriates preferring Hundi

Exporters in discomfort, expatriates preferring Hundi

12h | Videos
The first mosque in India was built Prophet Mohammad time

The first mosque in India was built Prophet Mohammad time

12h | Videos
Can your coworker be your closest friend?

Can your coworker be your closest friend?

22h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab